Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability
NilayKanti Dasa b✉, Anupam Dasa c d✉, Amrita Sila c d, Kunal Roya d, AmalKanti Dasa c d✉, Debabrata Bandyopadhyaya d
- aDepartment of Dermatology, Medical College, Institute of Postgraduate Education and Research, Kolkata, West Bengal, India
- bDr. Nilay Kanti Das, Devitala Road, Majherpara, Ishapore, 24 Paragans (N), West Bengal, India. E-mail: [email protected]
- cDepartment of Pharmacology, Medical College, Institute of Postgraduate Education and Research, Kolkata, West Bengal, India
- d1Department of Pharmacology, Medical College, Institute of Postgraduate Education and Research, Kolkata, West Bengal, India
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
BACKGROUND: Pityriasis rosea (PR) is an acute inflammatory dermatosis. The association of human herpes virus 6 and 7 suggests the utility of use of antiviral agents in this disease. AIMS AND OBJECTIVES: To evaluate the effectiveness and safety of acyclovir in the treatment of PR. METHODS: An observer-blind, randomized (1:1), parallel group, add-on trial was conducted on 24 adult patients with PR. Subjects of both Group A and B received the standard of care in the form of cetirizine 10 mg OD and calamine. Group A in addition received acyclovir 400 mg tablets thrice daily for 7 days. Both groups were followed up for four consecutive weeks for assessment of effectiveness and adverse events. RESULTS: Group A complained of significantly fewer new lesions than Group B (P = 0.046). A complete response was obtained in all patients of Group A and 83% patients of Group B at the end of the follow up period. There was significant reduction in both lesional score and pruritus at second week follow-up in Group A and third week follow-up in Group B (P < 0.05). Minor adverse effects were observed in both treatment arms. CONCLUSION: Acyclovir offered rapid resolution of clinical severity of PR from second week onwards without significantly increased adverse events as compared to supportive therapy alone.
TL;DRAcyclovir offered rapid resolution of clinical severity of PR from second week onwards without significantly increased adverse events as compared to supportive therapy alone. (Semantic Scholar)